Apr. 24, 2025

Beamion BCGC-1: A Phase Ib and Phase II trial of zongertinib in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ mBC and mGEAC (1479-0012/ Beamion BCGC-1)